Posts By: admin

At KVK, we realize that all that stands between the American public and a dangerous shortage of prescription medication are the men and women that make up the pharmaceutical industry.  If these unsung-heroes do not make it to work, patients face dangerous drug shortages.  KVK is immensely proud of the dedication of our essential employees…. Read more »

KVK Tech, Inc. Announces 1-2-3 Savings Program for Lomaira™ (phentermine hydrochloride USP) 8 mg Tablets, CIV Cost Savings for Lomaira Patients NEWTOWN, PA., May 2, 2018 /PRNewswire/ — KVK Tech, Inc. (KVK), a leading American developer, manufacturer, and marketer of FDA-approved pharmaceuticals today announced the LOMAIRA 1-2-3 program. The 1-2-3 program allows patients to start… Read more »

KVK Tech, Inc. Announces Partnership with Medix for International Expansion into Mexico. NEWTOWN, PA., Nov 14, 2017 /PRNewswire/ — KVK Tech, Inc. (KVK), a leading American developer, manufacturer, and marketer of FDA-approved pharmaceuticals today announced a strategic partnership with Productos Medix S.A. de C.V. (“Medix”), a leader in pharmaceutical obesity products in Mexico. The licensing… Read more »

KVK Tech Announces FDA-Approval of Lomaira™ (phentermine hydrochloride USP) 8 mg tablets, CIV, A Low-Cost, Low-Dose Phentermine That Can Be Used Up to Three Times Daily for Weight Reduction Newtown, PA, Sept. 20, 2016 — KVK Tech, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Lomaira™ (phentermine hydrochloride USP) 8… Read more »